A Balancing Act: Safety and Success in CMV Management for HCT Patients: A Clinical Forum®
Released On
April 4, 2025
Expires On
April 3, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology, Infectious Disease, Internal Medicine, and Transplantation
Topic(s)
Leukemia, Lymphoma, Multiple Myeloma
Provider Statement
This activity is jointly provided by RMEI Medical Education, LLC and Medical College of Wisconsin.
Supporter Statement
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Pharmacists — 1.0 Contact Hours
- Nurses — 1.0 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Hematologists/oncologists, transplantation, internal medicine, and infectious disease clinicians
Program Overview
Cytomegalovirus (CMV) is a serious pathogen that leads to considerable illness and death in hematopoietic cell transplant (HCT) patients. The landscape for CMV prevention and treatment in this vulnerable population continues to evolve, with newer antiviral therapies offering efficacy and minimal side effects.
Optimal CMV management should include an individualized approach based on current guidelines, transplant conditioning regimens, treatment toxicities, and potential CMV drug resistance. Join our distinguished panel as they review state-of-the-art therapeutic considerations for managing CMV in HCT patients, including insights on a challenging clinical case from their practice.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select evidence-based treatments for hematopoietic cell transplant (HCT) patients with cytomegalovirus (CMV) considering newer antiviral medications and guideline recommendations
- Identify critical limitations to conventional CMV therapies, including side-effect toxicities, that often result in suboptimal outcomes
- Formulate individualized plans for monitoring and treating HCT patients with CMV, including those with refractory or drug-resistant disease
Faculty
Genovefa Papanicolaou, MD
Director, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Medicine
Weill Cornell Medical College, Cornell University
New York, NY
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Professor and Chair
G. P. Bodey, Sr. Distinguished Professorship, Infectious Diseases
Director, Clinical Virology Research
Department of ID/IC/EH
UT MD Anderson Cancer Center
Houston, TX
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and the Medical College of Wisconsin. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s)
(0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number — JA4008290-9999-25-002-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosures of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has relevant financial relationship(s) with Adagio Therapeutics, ADMA Biologics, AiCuris, Ansun Pharmaceuticals, Astellas, InflaRX, Janssen, Karius, Merck, Moderna, Oxford Immunotec, Partner Therapeutics, Roche/Genentech, Shinogi, Takeda, Tether (Consultant); AiCuris, Ansun Pharmaceuticals, Eurofins-Viracor, Genentech, Karius, Oxford Immunotec, Merck, Takeda (Researcher).
Genovefa Papanicolaou, MD, has relevant financial relationship(s) with Genentech, Regeneron, Symbio (Consultant); Merck (Advisor); Advarra, Merck, Takeda (Grant/Research Support); Advarra, Allovir, Trellis Bioscience (Independent Contractor).
Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Instructions for Receiving Credit
To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
There is no fee to participate.
In order to claim MOC points, users must:
- Review and successfully complete the activity
- Proceed to the evaluation and provide your ABIM ID and date of birth
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion
For Pharmacists: You must provide your NABP eProfile ID and Date of Birth (MMDD format) in order to receive credit for the activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!*
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
If you have questions about this activity, please contact RMEI at [email protected].